| Literature DB >> 26609053 |
Dongwon Choi1, Swapnika Ramu1, Eunkyung Park1, Eunson Jung1, Sara Yang1, Wonhyeuk Jung1, Inho Choi2, Sunju Lee1, Kyu Eui Kim1, Young Jin Seong1, Mingu Hong1, George Daghlian1, Daniel Kim1, Eugene Shin1, Jung In Seo1, Vicken Khatchadourian1, Mengchen Zou3, Wei Li3, Roger De Filippo4, Paul Kokorowski4, Andy Chang4, Steve Kim4, Ana Bertoni5, Tania Weber Furlanetto6, Sung Shin7, Meng Li8, Yibu Chen8, Alex Wong1, Chester Koh9, Jan Geliebter10, Young-Kwon Hong11.
Abstract
Papillary thyroid cancer (PTC) is one of the most common endocrine malignancies associated with significant morbidity and mortality. Although multiple studies have contributed to a better understanding of the genetic alterations underlying this frequently arising disease, the downstream molecular effectors that impact PTC pathogenesis remain to be further defined. Here, we report that the regulator of cell fate specification, PROX1, becomes inactivated in PTC through mRNA downregulation and cytoplasmic mislocalization. Expression studies in clinical specimens revealed that aberrantly activated NOTCH signaling promoted PROX1 downregulation and that cytoplasmic mislocalization significantly altered PROX1 protein stability. Importantly, restoration of PROX1 activity in thyroid carcinoma cells revealed that PROX1 not only enhanced Wnt/β-catenin signaling but also regulated several genes known to be associated with PTC, including thyroid cancer protein (TC)-1, SERPINA1, and FABP4. Furthermore, PROX1 reexpression suppressed the malignant phenotypes of thyroid carcinoma cells, such as proliferation, motility, adhesion, invasion, anchorage-independent growth, and polyploidy. Moreover, animal xenograft studies demonstrated that restoration of PROX1 severely impeded tumor formation and suppressed the invasiveness and the nuclear/cytoplasmic ratio of PTC cells. Taken together, our findings demonstrate that NOTCH-induced PROX1 inactivation significantly promotes the malignant behavior of thyroid carcinoma and suggest that PROX1 reactivation may represent a potential therapeutic strategy to attenuate disease progression. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26609053 PMCID: PMC4738160 DOI: 10.1158/0008-5472.CAN-15-1199
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701